Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 12:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Open Label (Avatrombopag tablets) Clear all
Completed Phase 3 Interventional Results available

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

NCT04516967
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Avatrombopag, Placebo
Drug
Lead sponsor
Sobi, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Long Beach, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 24, 2026, 12:45 PM EDT
Completed Phase 4 Interventional Results available

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

NCT04638829
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Avatrombopag Oral Tablet
Drug
Lead sponsor
Sobi, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Tucson, Arizona • Whittier, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 24, 2026, 12:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects

NCT01289509
View directory record Official record
Conditions
Idiopathic Thrombocytopenia Purpura
Interventions
E5501, Drug: E5501
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 24, 2026, 12:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects

NCT01260155
View directory record Official record
Conditions
Healthy Subjects
Interventions
E5501
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 24, 2026, 12:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal

NCT01759394
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Avatrombopag maleate 40 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 24, 2026, 12:45 PM EDT
Completed Phase 3 Interventional Results available

Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers

NCT03471078
View directory record Official record
Conditions
Chemotherapy-induced Thrombocytopenia
Interventions
Avatrombopag, Placebo Oral Tablet
Drug
Lead sponsor
Sobi, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
14
States / cities
Anaheim, California • Bakersfield, California • Riverside, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 24, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

NCT00625443
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Blinded (placebo), Open Label (Avatrombopag tablets), Blinded (Avatrombopoag tablets)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
Anaheim, California • Bakersfield, California • Manchester, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Sep 24, 2026, 12:45 PM EDT